Detection of Low-Molecular-Weight Mast Cell-Activating Factors in Serum From Patients With Chronic Spontaneous Urticaria.

BACKGROUND AND OBJECTIVES Functionally active autoantibodies to IgE and to the high-affinity IgE receptor (FcεRI) can be detected in serum in about 40% of patients with chronic spontaneous urticaria (CSU). Recent studies showed that serum from patients with CSU can induce activation of mast cells, irrespective of whether they carry high-affinity IgE receptors. To evaluate mast cell activation induced by factors in the serum of CSU patients with a molecular weight lower than that of autoantibodies. METHODS Eight CSU patients and 5 healthy controls were evaluated. Whole serum and serum fractionated at 100, 50, and 30 kDa were used to stimulate in vitro LAD2 mast cells. The enzymatic activity of β-hexosaminidase was evaluated in supernatants and cell pellets as a measure of mast cell degranulation. RESULTS Mean (SEM) release of mast cell β-hexosaminidase induced by whole serum from CSU patients was higher than that induced by serum from the healthy controls (14.4 [2.7%] vs 5.1 [2.4%]; P=.027). In addition, serum fractions below 100 kDa and below 50 kDa from CSU patients induced mast cell degranulation that was significantly higher than that induced by the corresponding fractions in sera from healthy controls (10.2% [1.4%] vs 3.8% [1.9%] [P=.024] and 10.1% [1.2%] vs 3.9% [1.7%] [P=.012], respectively). In 4 CSU patients, we evaluated serum fractions <30 kDa, which retained their capacity to activate mast cells (11.0% [0.7%]). CONCLUSIONS This study shows that sera from CSU patients may contain low-molecular-weight mast cell-activating factors other than autoantibodies. These factors could be an additional mechanism contributing to the pathogenesis of CSU.

[1]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[2]  C. Pucillo,et al.  Mast cells are critically involved in serum‐mediated vascular leakage in chronic urticaria beyond high‐affinity IgE receptor stimulation , 2011, Allergy.

[3]  R. Hamilton,et al.  Independent Evaluation Of A Commercial Test For “Autoimmune” Urticaria In Normal And Chronic Urticaria Subjects , 2009 .

[4]  R. Asero,et al.  Chronic urticaria: novel clinical and serological aspects , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  A. Kaplan,et al.  Mechanisms of autoimmune activation of basophils in chronic urticaria. , 2001, The Journal of allergy and clinical immunology.

[6]  A. Kaplan,et al.  Complement dependence of histamine release in chronic urticaria. , 1999, The Journal of allergy and clinical immunology.

[7]  A. Amadori,et al.  Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. , 1999, The Journal of allergy and clinical immunology.

[8]  J. Kinet,et al.  Comparative studies of functional and binding assays for IgG anti-FcϵRIα (α-subunit) in chronic urticaria ☆ ☆☆ ★ ★★ , 1998 .

[9]  J. Kochan,et al.  Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. , 1993, The New England journal of medicine.

[10]  M. Greaves,et al.  Detection of circulating histamine releasing autoantibodies with functional properties of anti‐IgE in chronic urticaria , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  R. Leeming,et al.  Preliminary identification of a low molecular weight serological mediator in chronic idiopathic urticaria , 1988, The British journal of dermatology.

[12]  A. Kaplan,et al.  Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. , 1988, The Journal of investigative dermatology.